Michael Roppolo, MD
Nephrology · Baton Rouge, LANPI 1639172687
Payments from drug & device makers
Across 512 payments — averaging $872.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$242K
- Akebia Therapeutics Inc$45K
- Boehringer Ingelheim$43K
- Biogen$39K
- Bayer$30K
- AstraZeneca$13K
- plus $34K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 51 | $242,466 |
| Akebia Therapeutics Inc | 93 | $45,193 |
| Boehringer Ingelheim | 10 | $43,304 |
| Biogen | 2 | $38,939 |
| Bayer | 24 | $29,882 |
| AstraZeneca(2 entities) | 63 | $12,952 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $11,106 |
| Ardelyx, Inc. | 16 | $10,625 |
| Fresenius USA Marketing, Inc. | 102 | $5,933 |
| Boehringer Ingelheim Limited | 3 | $2,382 |
| Vifor Pharma, Inc. | 50 | $919 |
| Mallinckrodt Hospital Products Inc. | 10 | $383 |
| Otsuka America Pharmaceutical, Inc. | 15 | $362 |
| Medtronic | 7 | $359 |
| Amgen(2 entities) | 16 | $306 |
| Novartis | 9 | $299 |
| Baxter Healthcare | 2 | $206 |
| Aurinia Pharma U.S., Inc. | 4 | $177 |
| Sanofi | 2 | $152 |
| OPKO Pharmaceuticals, LLC | 8 | $138 |
| GSK | 3 | $133 |
| Nxstage Medical, Inc. | 2 | $101 |
| W. L. Gore & Associates, Inc. | 1 | $67 |
| Calliditas Therapeutics US Inc. | 3 | $64 |
| Abiomed | 1 | $60 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Ultragenyx Pharmaceutical Inc. | 3 | $54 |
| ANI Pharmaceuticals, Inc. | 3 | $52 |
| Novo Nordisk | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Veloxis Pharmaceuticals, Inc. | 1 | $16 |
| Boehringer Ingelheim International GmbH | 1 | $1 |
How this compares
$446,758 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Baton Rouge
- Christopher LuscyBaton Rouge$1.1M
- Jones SamuelBaton Rouge$207K
- Amin KamyarBaton Rouge$88K
- Damodar KumbalaBaton Rouge$16K
- Robert LandryBaton Rouge$13K
- Raynold CoronaBaton Rouge$12K
- Kiran PadigalaBaton Rouge$6K
- Sreedhara AllaShreveport$1.2M
- Marwan KaskasShreveport$968K
- Juan Carlos VelezNew Orleans$801K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.